Medpace Investors Face June 8 Deadline to Seek Lead Role in Securities Suit Over Book-to-Bill Claims

Overview

• Investors are being urged to move by June 8 to seek appointment as lead plaintiff in Durbin v. Medpace in the Southern District of Ohio under Sections 10(b) and 20(a).
• Plaintiffs allege Medpace overstated its fourth-quarter 2025 book-to-bill guidance and downplayed rising project cancellations, which they say misled shareholders.
• Medpace later reported a 1.04 book-to-bill for the quarter, below its 1.15 target, and cited elevated cancellations, after which the stock fell about 16% the next day.
• Law firms say they are investigating reports of further cancellation increases, a possible drop in the first-quarter 2026 book-to-bill to about 0.88, and the president’s plan to resign, with shares sliding roughly 23% during April 23 trading on those reports.
• Book-to-bill compares new contract awards with billed work, so cancellations can quickly sap near‑term growth, and in a securities class action the lead plaintiff sets litigation strategy, typically with lawyers working on contingency.